Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

[Vitamin K antagonists: from discovery to pharmacogenetics].

Moreau C, Loriot MA, Siguret V.

Ann Biol Clin (Paris). 2012 Oct 1;70(5):539-51. doi: 10.1684/abc.2012.0740. Review. French.

PMID:
23047901
2.

[The pharmacogenetics of vitamin K antagonists: still a matter for discussion].

Moreau C, Siguret V, Loriot MA.

Rev Med Interne. 2010 May;31(5):361-8. doi: 10.1016/j.revmed.2009.07.014. Epub 2010 Apr 1. French.

PMID:
20362363
3.

Pharmacogenetics aspects of oral anticoagulants therapy.

Militaru FC, Vesa SC, Pop TR, Buzoianu AD.

J Med Life. 2015 Apr-Jun;8(2):171-5.

4.

[Optimalisation of treatment with vitamin K antagonists--the role of gene polymorphisms].

Stępień E, Wypasek E, Branicka A, Undas A.

Kardiol Pol. 2010;68 Suppl 5:S428-35. Review. Polish.

PMID:
22134997
5.

[Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].

Siguret V.

Pathol Biol (Paris). 2007 Jul;55(6):295-8. Epub 2007 Jul 3. French.

PMID:
17611042
6.

Effects on bleeding complications of pharmacogenetic testing for initial dosing of vitamin K antagonists: a systematic review and meta-analysis.

Franchini M, Mengoli C, Cruciani M, Bonfanti C, Mannucci PM.

J Thromb Haemost. 2014 Sep;12(9):1480-7. doi: 10.1111/jth.12647. Epub 2014 Jul 24. Review.

7.

[Pharmacogenetics of oral anticoagulants: individualized drug treatment for more efficacy and safety].

Loriot MA, Beaune P.

Rev Prat. 2007 Jun 30;57(12):1281-6. Review. French.

PMID:
17717937
8.

Influence of proton pump inhibitors and VKORC1 mutations on CYP2C9-mediated dose requirements of vitamin K antagonist therapy: a pilot study.

Brunner-Ziegler S, Jilma B, Magirr D, Sunder-Plassmann R, Giurgea GA, Hammer A, Margeta C, Brunner M, Koppensteiner R, Mannhalter C.

Br J Haematol. 2014 Nov;167(4):547-53. doi: 10.1111/bjh.13082. Epub 2014 Aug 21.

PMID:
25142093
9.

Pharmacogenetics of oral anticoagulants.

Daly AK, King BP.

Pharmacogenetics. 2003 May;13(5):247-52. Review.

PMID:
12724615
10.

Pharmacogenetics of vitamin K antagonists: useful or hype?

Lippi G, Franchini M, Favaloro EJ.

Clin Chem Lab Med. 2009;47(5):503-15. doi: 10.1515/CCLM.2009.140. Review.

PMID:
19397481
11.

Pharmacogenetics of warfarin.

Kamali F, Wynne H.

Annu Rev Med. 2010;61:63-75. doi: 10.1146/annurev.med.070808.170037. Review.

PMID:
19686083
12.

[Genetic predisposition to bleeding during oral anticoagulants treatment].

Montes Díaz R, Nantes O, Molina E, Zozaya J, Hermida J.

An Sist Sanit Navar. 2008 Sep-Dec;31(3):247-57. Review. Spanish.

13.

The c.-1639G>A polymorphism of the VKORC1 gene in Serbian population: retrospective study of the variability in response to oral anticoagulant therapy.

Kovac MK, Maslac AR, Rakicevic LB, Radojkovic DP.

Blood Coagul Fibrinolysis. 2010 Sep;21(6):558-63. doi: 10.1097/MBC.0b013e32833c2988.

PMID:
20581661
14.

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters.

Geisen C, Luxembourg B, Watzka M, Toennes SW, Sittinger K, Marinova M, von Ahsen N, Lindhoff-Last E, Seifried E, Oldenburg J.

Eur J Clin Pharmacol. 2011 Apr;67(4):371-81. doi: 10.1007/s00228-010-0950-y. Epub 2010 Nov 26.

15.

Vascular calcification: the price to pay for anticoagulation therapy with vitamin K-antagonists.

Chatrou ML, Winckers K, Hackeng TM, Reutelingsperger CP, Schurgers LJ.

Blood Rev. 2012 Jul;26(4):155-66. doi: 10.1016/j.blre.2012.03.002. Epub 2012 Apr 18. Review.

PMID:
22520397
16.

[Vitamin K epoxide reductase: Fresh blood for oral anticoagulant therapies].

Loriot MA, Beaune P.

Rev Med Interne. 2006 Dec;27(12):979-82. Epub 2006 Oct 11. Review. French.

PMID:
17070618
17.

Structural Modeling Insights into Human VKORC1 Phenotypes.

Czogalla KJ, Watzka M, Oldenburg J.

Nutrients. 2015 Aug 14;7(8):6837-51. doi: 10.3390/nu7085313. Review.

18.

A model predicting fluindione dose requirement in elderly inpatients including genotypes, body weight, and amiodarone.

Moreau C, Pautas E, Duverlie C, Berndt C, Andro M, Mahé I, Emmerich J, Lacut K, Le Gal G, Peyron I, Gouin-Thibault I, Golmard JL, Loriot MA, Siguret V.

Thromb Haemost. 2014 Apr 1;111(4):705-12. doi: 10.1160/TH13-07-0555. Epub 2013 Dec 12.

PMID:
24337438
19.

Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues.

Gage BF, Lesko LJ.

J Thromb Thrombolysis. 2008 Feb;25(1):45-51. Epub 2007 Oct 1. Review.

PMID:
17906972
20.

Warfarin pharmacogenomics: recommendations with available patented clinical technologies.

Borkowski AA, Kardani A, Mastorides SM, Thomas LB.

Recent Pat Biotechnol. 2014;8(2):110-5. Review.

PMID:
25185986

Supplemental Content

Support Center